VideoInsight: Video as a Tool to Improve Insight in Schizophrenia
Study Details
Study Description
Brief Summary
The deficit of awareness of pathology (or insight) is a common symptom in patients with schizophrenia and has a negative impact on the prognosis of the disease. Current treatments aren't effective enough on this symptom (Pijnenbord et al., 2013).
Previous studies have shown a positive impact of videos of patients themselves on insight but they lacked power. This technique needs more investigation. The study aims to improve the patient's awareness of pathology with a video of themselves recorded in the acute phase of their illness. Patients will watch this video after clinical stabilization. This is a randomized controlled and single blinded trial. A population of 60 patients (30 in each group) will be included. The impact on the insight, symptomatology, treatment adherence and functional remission will be evaluated.
The video of patient is useful for a personalized clinical follow-up. Its use for therapeutic purposes would be innovative and could be extended to other applications in psychiatry, especially as this tool is readily available.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
In everyday practice in psychiatry, some interviews are filmed in order to follow the clinical course and for educational purposes. But the videos are not used as a therapeutic tool for patients. This research project focuses on the therapeutic potential of these videos and particularly on the awareness of patients of their disorder (insight). Patients hospitalized for decompensation of their schizophrenic pathology will be filmed during structured interviews. After clinical stabilization patients will be proposed to participate to this trial. A group of patients (G1) will watch the video recorded in the acute phase of their illness. A control group (G2) will have a usual care without video or specific therapy. 48 hours after, the clinical impact et the evolution of insight of patients will be evaluated. Then follow-up visits will also be provided at one and four months with the same clinical evaluation, plus an evaluation of treatment adherence and functional remission. This study also includes qualitative interviews for group 1 after watching the video to explore the experience of patients in this situation of self-confrontation. The autobiographical memory will also be studied in this protocol. Tolerance of this experience will be assessed by a monitoring of emotions, specifically depressive affects and suicidal ideation. Adverse events will be reported and patients will always have the access to a psychiatrist if necessary.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental group with video 30 patients will watch the video of them in acute decompensation phase |
Other: Video self-observation
Patients will watch the video of them in acute decompensation phase then they will be asked about their emotions, their understanding and awareness of mental illness
Other Names:
|
| Sham Comparator: Control group without video 30 patients will not watch the video of them in acute decompensation phase, they pass a standard interview with psychometric scales |
Other: Non Self video observation
Patients will not watch the video of them in acute decompensation phase.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Unawareness of Mental Disorder (SUMD) [48 hours]
Scale to assess Unawareness of Mental Disorder (SUMD)
Secondary Outcome Measures
- Insight [48 hours]
Birchwood Insight Scale
- Cognitif Insight [48 hours]
Beck Cognitive Insight Scale
- Positive Symptom [48 hours]
Positive and Negative Symptom Scale
- Negative Symptom [48 hours]
Positive and Negative Symptom Scale
- Depression [48 hours]
Calgary Depression Scale for Schizophrenia
- Autobiographical Memory [48 hours]
Autobiographical Memory Test
- Medication Adherence [48 hours]
Medication Adherence Rating Scale
- Functional Remission (FROGS scale) [48 hours]
Evaluation of quality of daily life
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients with a diagnosis of schizophrenia or schizoaffective disorder according to the DSM 5
-
Age between 18 and 65 years
-
Patients initially hospitalized for acute decompensation of their schizophrenia or schizoaffective disorder according to the medical records and any medical certificates
-
Patients who agreed to be filmed during a standardized interview at screening (in acute decompensation phase of the disease at the beginning of hospitalization)
-
Clinical state compatible with the therapeutic experience and obtaining consent with a score on the scale of PANSS positive symptoms of less than 24
Exclusion Criteria:
-
Mental impairment moderate to severe
-
Central nervous system disease or severe head trauma
-
Chronic alcohol dependence
-
Patients hospitalized for a social problem or otherwise, without acute decompensation of their schizophrenia or schizoaffective disorder as assessed by the referring psychiatrist
-
Patients deprived of liberty by judicial decision
-
Pregnant and breastfeeding women
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospital of Montpellier | Montpellier | France | 34295 | |
| 2 | University Hospital of Nîmes | Nîmes | France | 30029 |
Sponsors and Collaborators
- University Hospital, Montpellier
- Centre Hospitalier Universitaire de Nīmes
Investigators
- Study Director: Aurélie SCHANDRIN, MD, University hospital of Nîmes
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UF 9545